BioCentury
ARTICLE | Product R&D

Bias-less bispecifics

How Merus’ HER2/3 bispecific could succeed in breast cancer where HER3 mAbs failed

May 24, 2018 11:17 PM UTC

Taking a leaf from the small molecule playbook, cancer play Merus N.V. is bringing unbiased screening to the bispecifics space. The biotech is betting the approach can discover bispecific antibodies with novel activity against known targets.

Last week in Cancer Cell, Merus showcased its process and unveiled the mechanism behind its lead candidate MCLA-128, a bispecific against HER2 and HER3...